Last year was not without its pitfalls, however. Most notable among them was a setback in Food and Drug Administration phase III trials for the company's most advanced compound, Trofak, which resulted in a 25 percent plummet in stock price over a three-day period in mid-autumn. Nonetheless, industry watchers, financial and scientific alike, are bullish on Synergen's future as the new year dawns.
Certainly, Synergen does not have a corner on good science, good management, or even luck within the biotechnology sector. But it does have all three, and looking at the firm's successful formula may give a hint as to why Synergen now is widely recognized by industry analysts as being among the top-tier biotechnology firms.
Unlike most biotechs launched during the early 1980s, Synergen was founded on the reputation of a team of scientists, rather than a potential product or process. University of Colorado scientists Larry Soll, David ...
